One Case of Transaminase Elevation Induced by Liraglutide Injection

Abstract

CLC Number:

R994.11

ZHANG Fan, WANG Li-xia. One Case of Transaminase Elevation Induced by Liraglutide Injection[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 372-373.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I6/372

[1] 李博, 高蕊, 唐旭东, 等. 药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]. 中国新药杂志, 2014, 23(12):1465-1470.
[2] 熊佩华, 韩俊霞, 成兴波, 等.2 型糖尿病患者胰高血糖素样肽1水平的变化及其临床意义的研究[J].中国糖尿病杂志, 2013, 21(4) : 306-308.
[3] 张存志, 邸力强, 曹瑞芳, 等. 利拉鲁肽对治疗欠佳 2 型糖尿病患者疗效观察及安全性研究[J]. 实用糖尿病杂志, 2014, 10(5):15-17.
[4] 陈奇盛, 黄翠娟. 二甲双胍联合利拉鲁肽治疗2型糖尿病临床研究[J]. 中外医疗, 2016, 35(35) :121-123.
[5] 曲庚汝, 姜莉莉, 吴军. 利拉鲁肽与甘精胰岛素治疗型糖尿病的疗效比较[J]. 中国新药与临床杂志, 2013, 32(9):701-704.
[6] 李晓玲, 朱旅云, 单巍, 等. 加用利拉鲁肽治疗单用胰岛素效果不佳的 2 型糖尿病患者的临床观察[J]. 实用糖尿病杂志, 2014, 10(3):33-34.
[7] 李骏, 梁金玲, 麦高阳. 百令胶囊联合利拉鲁肽治疗早期糖尿病肾病的疗效观察[J]. 现代药物与临床, 2016, 31(2):174-177.
[8] 曹筱佩, 阳池娇. 人胰高血糖素样肽-1类似物的临床疗效及不良反应[J]. 临床药物治疗杂志, 2013,11(1): 45-48.
[9] 陈群峰, 王永祥. 利拉鲁肽临床研究进展[J]. 世界临床药物, 2013, 34(5):312-315.
[10] 贾王平, 郭代红, 田小燕, 等. 79家医院1110例药物性肝损害不良反应/事件分析[J]. 中国药物警戒, 2017, 14(8):481-485.
[11] 董雅芬, 杨秋娅, 胡滨,等. 盐酸胺碘酮注射液致急性肝肾损伤1例[J]. 中国药物警戒, 2017, 14(8):502-503.
[12] 贾晓英,李莎. 跌打生骨颗粒致肝损害 1例[J]. 中国药物警戒, 2017, 14(11):703-704.
[13] Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue Liraglutide[J]. Diabetes, 2007, 56(S1):A-145.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

One Case of Transaminase Elevation Induced by Liraglutide Injection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics